Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$1.41M$1.41M−56.3% vs Q2 2023 Net Income-$5.76M-$5.76MN/M vs Q2 2023 EPS Diluted-$0.03-$0.03N/M vs Q2 2023 Operating Income-$5,867,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,226,000N/M Margins · derivedOperating margin-416.7%−260.9 pt vs Q2 2023
Net margin-409.1%−247.0 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end